Merck's Biosimilars Business, from Parexel's Perspective

March 3, 2011

Applied Clinical Trials

Merck's Biosimilars Business, From Parexel's Perspective

Josef von Rickenbach, Chairman and CEO of Parexel, discusses why Parexel won the Merck biosimilars’ business, differences in recruitment for biosimilars, and trends for 2011, including the 20-year promise of technology now being realized.